Fig. 7

UC/PL-MSC-CM inhibits MRTF-A nuclear localization in HIMFs. HIMFs were treated with TGF-β1 (5 ng/mL), co-cultured with or without UC/PL-MSC-CM, stained with MRTF-A antibodies, and counterstained with DAPI. A (A–C) no treatment; (D–F) treatment with TGF-β1; (G–I) treatment with TGF-β1 and PL-MSC-CM; (J–L) treatment with TGF-β1 and UC-MSC-CM; (c, f, i, l) Enlarged images of the region (within the white box of C, F, I, and L, each). B The nuclear-to-cytoplasmic ratio of MRTF-A was determined for each condition as described in the "Methods" section. Data are expressed as means ± SEM. ^#P < .05 versus the control; ^*P < .05 and ^**P < .01 versus the TGF-β1 treatment only (ANOVA w/ Tukey). NS, not significant (Mann–Whitney U test); Scale bars, 100 μm; original magnification, × 200 (A)